www.bpsmedicine.com

Table 2
Changes in HRV related to physical treatments for depression other than SSRIs or TCAs.
Measure	Heart Rate	SDNN	SDANN	RMSSD	LF	lnHF	HF	LF/HF	CV	pNN50
Units	bpm	ms	ms	ms	ms²	ms²	ms²	ratio	ratio	percent

Reboxetine short supine
Mean Baseline Value	82.60			18.50	946.00		354
Mean Percent Change	5.6%			-1.6%	-18.9%		21.8%
Number of Comparisons	1			1	1		1
Mean Effect Size	1.32 ns			-0.04 ns	-0.38 ns		0.79 ns
Nefazodone short supine
Mean Baseline Value	75.80	30.08		24.50	864.00		480	2.97	3.80
Mean Percent Change	-5.9%	14.3%		4.1%	-5.7%		-10.4%	-5.7%	-2.6%
Number of Comparisons	1	1		1	1		1	1	1
Mean Effect Size	-1.60 *	0.08 ns		0.11 ns	-0.08 ns		-0.20 ns	-0.16 ns	-0.21 ns
Bupropion short supine
Mean Baseline Value				28.10
Mean Percent Change				-42.7%
Number of Comparisons				1
Mean Effect Size				-1.99 *
Mirtazapine short supine
Mean Baseline Value	66.00	49.60				6.50			5.40
Mean Percent Change	15.29%	-35.7%				-21.5%			-25.9%
Number of Comparisons	1	1				1			1
Mean Effect Size	3.10 *	-2.47 *				-1.81 *			-3.97 *
ECT short supine
Mean Baseline Value					548.00		264.00
Mean Percent Change					-42.9%		50.4%
Number of Comparisons					1		1
Mean Effect Size					-0.88 ns		0.84 ns
ECT 24 h
Mean Baseline Value		69.65								8.64
Mean Percent Change		6.2%								34.3%
Number of Comparisons		1								1
Mean Effect Size		0.51 ns								0.90 ns

All treatments on this table are represented by only one study except ECT where the two studies employed different recording times. ns indicates that original study or our reanalysis showed the change as non-significant, * indicates that the original study reported that the change was significant (p < .05).
van Zyl et al. BioPsychoSocial Medicine 2008 2:12 doi:10.1186/1751-0759-2-12

Table 2